XNCR Xencor Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: XNCR

Price (delayed)

$14.08

Market cap

$1.04B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.29

Enterprise value

$1.2B

?
Relative Growth: Rel. Growth: 7
Relative Strength: Rel. Strength: 72
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 40

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in ...

Highlights
Xencor's debt has decreased by 21% YoY and by 7% QoQ
XNCR's quick ratio is up by 8% year-on-year and by 3.3% since the previous quarter
The company's net income has shrunk by 88% QoQ but it rose by 17% YoY
The EPS has shrunk by 85% QoQ but it has increased by 25% YoY
XNCR's revenue is down by 23% year-on-year and by 22% since the previous quarter
The gross profit has decreased by 23% YoY and by 22% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.xencor.com
Peers: AMGN MGNX MRK ABBV

Key stats

What are the main financial stats of XNCR

XNCR stock price

How has the Xencor stock price performed over time
Intraday
0.5%
1 week
15.41%
1 month
24.49%
1 year
67.42%
YTD
-8.03%
QTD
16.75%

Financial performance

How have Xencor's revenue and profit performed over time
Revenue
$97.36M
Gross profit
$97.36M
Operating income
-$212.18M
Net income
-$172.42M
Gross margin
100%
Net margin
-177.1%
Xencor's net margin has shrunk by 142% QoQ and by 9% YoY
The company's net income has shrunk by 88% QoQ but it rose by 17% YoY
XNCR's operating margin has dropped by 66% year-on-year and by 54% since the previous quarter
Xencor's operating income has decreased by 27% YoY and by 20% from the previous quarter

Price vs fundamentals

How does XNCR's price correlate with its fundamentals

Growth

What is Xencor's growth rate over time

Valuation

What is Xencor stock price valuation
XNCR P/E details
P/E
N/A
P/B
2
P/S
10.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.37
The EPS has shrunk by 85% QoQ but it has increased by 25% YoY
XNCR's P/B is 43% above its last 4 quarters average of 1.4 but 4.8% below its 5-year quarterly average of 2.1
XNCR's equity is down by 19% year-on-year and by 19% since the previous quarter
XNCR's P/S is 55% above its last 4 quarters average of 7.0 and 22% above its 5-year quarterly average of 8.9
XNCR's revenue is down by 23% year-on-year and by 22% since the previous quarter

Efficiency

How efficient is Xencor business performance
The ROIC has plunged by 157% from the previous quarter but it has grown by 5% YoY
The ROA has plunged by 97% from the previous quarter but it has grown by 9% YoY
XNCR's ROE has plunged by 97% from the previous quarter but it is up by 11% YoY
The ROS has decreased by 9% YoY

Dividends

What is XNCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XNCR.

Financial health

How did Xencor financials performed over time
The total assets has declined by 19% year-on-year and by 16% since the previous quarter
XNCR's total liabilities is down by 16% year-on-year and by 8% since the previous quarter
Xencor's debt is 66% lower than its equity
Xencor's debt has decreased by 21% YoY and by 7% QoQ
XNCR's equity is down by 19% year-on-year and by 19% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.